# Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)

> **NCT00002036** · PHASE1 · COMPLETED · sponsor: **Abbott** · enrollment: 12 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Anti-HIV Immune Serum Globulin (Human)

## Key facts

- **NCT ID:** NCT00002036
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 12 (—)
- **Last updated:** 2009-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002036, "Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00002036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*